This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Destors, J.M. Articles by Boissel, J.P. Search for Related Content PubMed PubMed Citation Articles by Destors, J.M. Articles by Boissel, J.P. Social Bookmarking                         What's this?

Failure of a Pure Anti-Platelet Drug to Decrease the Number of Attacks More Than Placebo in Patients With Raynaud's Phenomenon

Unité de Pharmacologie Clinique, Hôpital Neuro-Cardiologique, Lyon, France

E. Gauthier

Unité de Pharmacologie Clinique, Hôpital Neuro-Cardiologique, Lyon, France

S. Lelong

Unité de Pharmacologie Clinique, Hôpital Neuro-Cardiologique, Lyon, France

J.P. Boissel

Unité de Pharmacologie Clinique, Hôpital Neuro-Cardiologique, Lyon, France

Fifty-eight patients with Raynaud's phenomenon were randomly allocated in a six week double-blind clinical trial in parallel groups to compare the efficacy of a pure antiplatelet agent, ticlopidine (250 mg b.i.d.) with that of a placebo. There was no significant difference between the two treatments in percent re duction of weekly number of attacks and in subjective improvement assessed by both patient and investigator. It is unlikely that platelets are involved in the mechanisms of Raynaud's crisis.

Angiology, Vol. 37, No. 8, 565-569 (1986)
DOI: 10.1177/000331978603700802


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?